硼替佐米联合化疗及自体移植治疗原发性浆细胞白血病2例并文献复习  

Plasma cell leukemia:report of 2 de novo cases treated with bortezomib containing autologous stem-cell transplantation and review of the literature

作　　者：姜波[1] 阎嶂松[1] 王华[2] 刘兵城[1] 魏嘉璘[1] 韩明哲[1] 

机构地区：[1]中国医学科学院中国协和医科大学血液学研究所血液病医院造血干细胞移植中心,天津300020 [2]烟台毓璜顶医院血液科

出　　处：《临床血液学杂志》2010年第6期651-653,657,共4页Journal of Clinical Hematology

摘　　要：目的:探讨硼替佐米序贯自体外周血干细胞移植治疗原发性浆细胞白血病的疗效。方法:报道2例经硼替佐米治疗达到完全缓解(CR)或非常好的部分缓解(VGPR),顺利进行自体外周血干细胞移植的原发性浆细胞白血病病例并复习相关文献。结果:硼替佐米对原发浆细胞白血病疗效显著,不影响干细胞动员与采集,联合自体周血干细胞移植,可有效提高患者生活质量。结论:硼替佐米联合化疗及自体移植可能会改善原发性浆细胞白血病的预后。Objective：To investigate the efficacy of combination of bortezomib and autologous stem-cell transplantation in the management of primary plasma cell leukemia（PPCL） .Method：Two patients achieved complete remission or very good partial remission with bortezomib-containing chemotherapy followed by autologous peripheral blood stem cell transplantation.Result：Bortezomib demonstrates high potency in the treatment of PCL and does not impair the mobilization of peripheral blood stem cells for the autologous stem cell transplantation.The combination of bortezomib and ASCT is an effective management stratety for PCL.Conclusion：Bortezomib containing chemotherapy and autologous stem-cell transplantation may improve the outcome of PCL.

关 键 词：原发性浆细胞白血病 硼替佐米 干细胞移植 

分 类 号：R733.7[医药卫生—肿瘤]